Alpine Immune Sciences, Kite Pharma deal

Alpine granted Kite exclusive, worldwide rights to develop and commercialize chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies against two undisclosed cancer targets using Alpine’s transmembrane immunomodulatory protein (TIP) platform. Alpine will receive $5 million up front and is eligible to receive up to $530 million in research, clinical and regulatory milestones, plus low single-digit royalties. ...